Study to evaluate the benefits and any risks of the delayed administration of tacrolimus in a combined regimen of mycophenolate mofetil and monoclonal anti-IL2R antibodies (daclizumab), in comparison with a standard steroid + tacrolimus double drug regimen
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
94
Unnamed facility
Bologna, Italy
Unnamed facility
Genova, Italy
Unnamed facility
Milan, Italy
Unnamed facility
Napoli, Italy
Unnamed facility
Incidence of first acute rejection
Time frame: 3 months
Overall frequences of acute rejection episodes
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
oral
Padua, Italy
Unnamed facility
Roma, Italy
Unnamed facility
Torino, Italy
Unnamed facility
Udine, Italy